This latest analysis is an extension of the COAPT trial, which had examined the safety and effectiveness of TMVR with the MitraClip device after two years.

In fact, drinking decaffeinated coffee was associated with a significant increase in heart failure risk.

According to a new study published in Circulation, ablation was associated with numerous benefits over standard drug therapy.

Manufactured by Novartis under the name Entresto, the medication is now also approved for treating HFpEF. 

Heart failure patients are also more likely to be readmitted than they were in the recent past. 

Two specialists have shared their own perspective on the updated ACC/AHA guidelines in Circulation.

However, treatment with sacubitril/valsartan did not lead to improvements in hospitalizations for heart failure or all-cause mortality.

Calcium supplements, the researchers emphasized, should be prescribed with caution.